REFERENCES
- Fleischhack G, Graf N, Hasan C, . [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)—an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study]. Klin Padiatr. 1996;208:229–235.
- Fleischhack G, Hasan C, Graf N, . IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998;102:647–655.
- Yalman N, Sarper N, Devecioğlu O, . Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr. 2000;42:198–204.
- Gandhi V, Estey E, Keating MJ, . Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116–124.
- Huhmann IM, Watzke HH, Geissler K, . FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol. 1996;73:265–271.
- Ferrara F, Palmieri S, Pocali B, . De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol. 2002;68:203–209.
- National Cancer Institute. Common Toxicity Criteria. Available at: http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/NCI_toxicity_table.pdf. Accessed 27 July 2010.
- Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993;7:81–107.
- Stahnke K, Ritter J, Schellong G, . [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study]. Klin Padiatr. 1992;204:253–257.
- Estey E, Thall P, Andreeff M, . Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671–678.
- Visani G, Tosi P, Zinzani PL, . FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ‘poor risk’ acute myeloid leukemias. Leukemia. 1994;8:1842–1846.
- Jackson G, Taylor P, Smith GM, . A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol. 2001;112:127–137.
- Dinndorf PA, Avramis VI, Wiersma S, . Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:2780–2785.
- Leahey A, Kelly K, Rorke LB, . A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML). J Pediatr Hematol Oncol. 1997;19:304–308.
- McCarthy AJ, Pitcher LA, Hann IM, . FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol. 1999;32:411–415.
- Anderlini P, Luna M, Kantarjian HM, . Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996;10:600–608.
- Goodman ER, Fiedor PS, Fein S, . Fludarabine phosphate: a DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am Surg. 1996;62:435–442.